SCHEDULE: BlackRock Discloses 8.5% Stake in Myriad Genetics
Ownership Filing Update
BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 7,976,163 shares, representing 8.5% of Myriad Genetics Inc.'s common stock.
Summary
- BlackRock, Inc. has filed an amendment to its Schedule 13G filing concerning Myriad Genetics Inc.
- As of March 31, 2026, BlackRock beneficially owns 7,976,163 shares of Myriad Genetics Inc. common stock.
- This ownership stake represents 8.5% of the total outstanding shares of the company's common stock.
- BlackRock holds sole voting power over 7,841,058 shares and sole dispositive power over 7,976,163 shares.
- The filing indicates that no single person has an interest exceeding five percent of the total outstanding common shares, excluding BlackRock's aggregate beneficial ownership.
- The filing is made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a routine ownership disclosure by a major institutional investor and does not provide new operational or financial information about Myriad Genetics Inc.
Positives
- Significant institutional ownership by BlackRock, Inc., indicating confidence in the company's long-term prospects.
- BlackRock's substantial voting and dispositive power suggests active engagement and potential influence on corporate governance.
Negatives
- The filing does not contain specific financial performance data or operational updates for Myriad Genetics Inc., focusing solely on BlackRock's ownership.
Risks
- Potential for increased market volatility if BlackRock decides to significantly alter its stake.
- Concentration of ownership could lead to increased influence by a single large shareholder on strategic decisions.
Future Outlook
This filing is an update to ownership disclosure and does not contain forward-looking statements or guidance from Myriad Genetics Inc.
Industry Context
StockSavvy.ai notes that significant institutional filings like this Schedule 13G from major asset managers such as BlackRock often signal sustained investor interest or a strategic shift in holdings within the biotechnology and diagnostics sector.
Stakeholder Impact
- Shareholders: The increased disclosure of significant institutional ownership may influence investor sentiment and trading activity.
- Management: May face increased scrutiny or engagement from BlackRock regarding corporate strategy and governance.
- Competitors: The filing provides insight into the investment landscape for Myriad Genetics Inc.
Next Steps
- Monitor future filings from BlackRock, Inc. for any changes in its beneficial ownership of Myriad Genetics Inc. stock.
- Observe Myriad Genetics Inc.'s strategic decisions and financial performance for insights into the company's direction.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Previous Power of Attorney dated for BlackRock, Inc. |
| 01/21/2025 | Effective date of the current Power of Attorney for BlackRock, Inc. |
| 03/31/2026 | Date of Event Which Requires Filing of this Statement (Amendment No. 5) |
| 04/07/2026 | Date of signature on the Schedule 13G filing. |
Keywords
Myriad Genetics, BlackRock, Schedule 13G, SEC Filing, Institutional Ownership, Common Stock, Beneficial Ownership, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.